Synthesis and pharmacological evaluation of combretastatin-A4 analogs of pyrazoline and pyridine derivatives as anticancer, anti-inflammatory and antioxidant agents

Three category of N 1 -phenyl pyrazoline ( 5a – e ), N 1 -phenyl-sulfonyl pyrazoline ( 6a – e), and pyridine analogs ( 8a – d ) of combretastatin-A4 were synthesized. The structures of compounds were verified by spectroscopic techniques. All the compounds were screened for their anticancer activity...

Full description

Saved in:
Bibliographic Details
Published in:Medicinal chemistry research 2018-04, Vol.27 (4), p.1226-1237
Main Authors: Shringare, Sadanand N., Chavan, Hemant V., Bhale, Pravin S., Dongare, Sakharam B., Mule, Yoginath B., Patil, Sandeep B., Bandgar, Babasaheb P.
Format: Article
Language:English
Subjects:
Analogs
Anti-inflammatory agents
Anticancer properties
Antioxidants
Antitumor activity
Ascorbic acid
Biochemistry
Biomedical and Life Sciences
Biomedicine
Cancer
Cell Biology
Diclofenac
Free radicals
Hydrogen peroxide
Inflammation
Original Research
Pharmacology
Pharmacology/Toxicology
Pyridines
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Three category of N 1 -phenyl pyrazoline ( 5a – e ), N 1 -phenyl-sulfonyl pyrazoline ( 6a – e), and pyridine analogs ( 8a – d ) of combretastatin-A4 were synthesized. The structures of compounds were verified by spectroscopic techniques. All the compounds were screened for their anticancer activity against MCF-7 cell line, antioxidant (DPPH, NO, SOR and H 2 O 2 ), and anti-inflammatory activity while compounds ( 8a – d ) additionally tested against K562 cell line. Compounds 8a and 8b showed substantial anticancer activity against MCF-7 cell line (GI 50  = 5.59 and 11.70 µM), although not comparable with adriamycin (GI 50  ⩽ 0.1 µM). However, none of the compound was active against the K562 cell line. Nevertheless, compound 8a displayed better cytostatic activity (TGI = 69.2 µM) than the standard drug adriamycin (TGI = 75.8 µM). Most of the compounds 5a, 5b, 5c, 5e, 6a, 6b, 6c , 6d, 6e 8a, and 8b have excellently inhibited all of the free radicals better than standard drug ascorbic acid, whereas compound 5c and 5b demonstrated significant anti-inflammatory activity comparable with diclofenac sodium, a standard anti-inflammatory drug.
ISSN:1054-2523
1554-8120
DOI:10.1007/s00044-018-2142-8